Corcept Therapeutics (CORT) Net Cash Flow Growth (3y) (2013 - 2026)
Powered by 
Analysis
Corcept Therapeutics (CORT) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -8.34% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 36.60% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -35.85% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 106.37% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 67.39% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.55% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 52.78% |
| 10 | Corcept Therapeutics | 11.76 Bn | 11.46 Bn | 252.09 Mn | 26.36% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 26.36% |
| Mar 31, 2026 | -27.01% |
| Dec 31, 2025 | -31.74% |
| Sep 30, 2025 | 15.10% |
| Jun 30, 2025 | 34.50% |
| Mar 31, 2025 | -34.35% |
| Dec 31, 2024 | 19.62% |
| Sep 30, 2024 | 135.16% |
| Jun 30, 2024 | -35.57% |
| Mar 31, 2024 | 37.44% |
| Dec 31, 2023 | -19.97% |
| Sep 30, 2023 | -29.39% |
| Jun 30, 2023 | -70.02% |
| Mar 31, 2023 | 63.75% |
| Dec 31, 2022 | 46.99% |
| Sep 30, 2022 | 46.27% |
| Jun 30, 2022 | -72.39% |
| Mar 31, 2022 | -58.25% |
| Dec 31, 2021 | -61.45% |
| Sep 30, 2021 | -31.46% |